Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2018 Mar;18(3):251-266.
doi: 10.1080/14737140.2018.1428092. Epub 2018 Jan 19.

The role of tumor angiogenesis as a therapeutic target in colorectal cancer

Francesca Battaglin  1   2 , Alberto Puccini  2   3 , Rossana Intini  1 , Marta Schirripa  1 , Alessandra Ferro  1   4 , Francesca Bergamo  1 , Sara Lonardi  1 , Vittorina Zagonel  1 , Heinz-Josef Lenz  2 , Fotios Loupakis  1
Affiliations
Review

The role of tumor angiogenesis as a therapeutic target in colorectal cancer

Francesca Battaglin et al. Expert Rev Anticancer Ther. 2018 Mar.

Abstract

Angiogenesis is a complex process regulated by several pro- and anti-angiogenic factors, thus the loss of its fine equilibrium plays a key role in colorectal cancer (CRC) development and progression. Therapeutic agents targeting VEGF/VEGFR signaling, the main regulator of this process, proved to be effective across different treatment lines in metastatic CRC (mCRC) and contributed greatly to improve patients' survival in recent years. Areas covered: This review aimed to summarize the actual body of knowledge available on the VEGF pathway in CRC, including currently available anti-angiogenic drugs and treatment challenges, mechanisms of resistance, promising predictive biomarkers and future perspectives. Expert commentary: Angiogenesis inhibition in subsequent lines of treatment is a valid strategy in the continuum of care of mCRC patients. In this scenario, the availability of multiple agents warrants to tailor therapy to an individualized approach. However, the validation of predictive biomarkers to aid therapeutic decisions remains an issue. Intrinsic and adaptive resistance to anti-angiogenic agents comprises distinct and intertwined processes, eventually leading to treatment failure and disease progression. The expanding knowledge on the mechanisms underlying the angiogenesis pathway, different potential treatment targets and mechanisms of tumor resistance, may lead to promising new perspectives in this field.

Keywords: Metastatic colorectal cancer; VEGF; aflibercept; angiogenesis; bevacizumab; biomarkers; ramucirumab; regorafenib; resistance.

PubMed Disclaimer

Conflict of interest statement

Declaration of interest

F Loupakis is an advisor/speaker for Amgen Inc, Bayer Healthcare, Eli Lilly and Company, and Roche. HJ Lenz has received clinical trial financial support from Merck Serono and Roche, and honoraria for advisory board membership and lectures from Bayer, Boehringer Ingelheim, Genentech, Merck Serono, and Roche. S Lonardi is an advisor/speaker for Amgen Inc, Bayer Healthcare, Eli Lilly and Company, Roche, and Sanofi. The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed. Peer reviewers on this manuscript have no relevant financial or other relationships to disclose.

Figures

Figure 1.
Figure 1.
Diagram of angiogenesis pathways and the role of anti-angiogenetic drugs available for metastatic colorectal cancer. Abbreviations: VEGF: Vascular endothelial growth factor; VEGFR: Vascular endothelial growth factor receptor; PlGF: Placental growth factor; Ang: angiopoietin; PDGF: Platelet-derived growth factor; PDGFR: Platelet-derived growth factor receptor; FGF: Fibroblast growth factor; FGFR: Fibroblast growth factor receptor; Dll4: Delta Like Canonical Notch Ligand 4; EGF: Epidermal growth factor; EGFR: Epidermal growth factor receptor.
See this image and copyright information in PMC

References

    1. Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell. 2011;144:646–674. - PubMed
    1. Ferrara N, Gerber HP, LeCouter J. The biology of VEGF and its receptors. Nat Med. 2003;9:669–676. - PubMed
    1. Shibuya M Vascular endothelial growth factor-dependent and -independent regulation of angiogenesis. BMB Rep. 2008;41:278–286. - PubMed
    1. Rolfo C, Bronte G, Sortino G, et al. The role of targeted therapy for gastrointestinal tumors. Expert Rev Gastroenterol Hepatol. 2014;8:875–885. - PubMed
    1. Olsson AK, Dimberg A, Kreuger J, et al. VEGF receptor signalling - in control of vascular function. Nat Rev Mol Cell Biol. 2006;7:359–371. - PubMed

Publication types

MeSH terms

Substances

LinkOut - more resources